Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia Aug 31, 2020
Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020 Jul 31, 2020
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada Apr 20, 2020
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June Apr 1, 2020